PET imaging agent could provide early diagnosis of rheumatoid arthritis

A novel PET tracer developed by Korean researchers can visualize joint inflammation and could provide early diagnosis of rheumatoid arthritis, a common autoimmune disease that causes chronic inflammation of joints and can lead to deformity and dysfunction. The study is reported in the featured basic science article in The Journal of Nuclear Medicine‘s May issue.

Activated macrophages, white blood cells that helps protect the body from harmful bacteria and infected cells, are known to play a pivotal role in rheumatoid arthritis (RA) development. Focusing on the translocator protein (TSPO), which is abundant in activated macrophages, researchers developed fluorine-18 (¹⁸F)-FEDAC, a radiolabeled ligand that targets TSPO and binds to it.

“This study is novel because it showed the value of ¹⁸F-FEDAC PET as an inflammation biomarker for early detection of rheumatoid arthritis, even before onset of clinical symptoms of joints,” explains Gi Jeong Cheon, MD, PhD, of Seoul National University College of Medicine in Seoul, Korea.

For the study, ¹⁸F-FEDAC was tested in a mouse model, using both ¹⁸F-FEDAC and ¹⁸F-FDG PET imaging. Microscopic examinations of tissue were performed to evaluate macrophages and TSPO expression.

Results showed increased TSPO mRNA and protein expression in activated macrophages, and uptake of ¹⁸F-FEDAC in activated macrophages was higher than it was in non-activated cells. In addition, ¹⁸F-FEDAC uptake by arthritic joints increased early on (day 23), whereas ¹⁸F-FDG uptake did not. However, ¹⁸F-FDG uptake by arthritic joints increased at later stages (day 37) to a higher level than ¹⁸F-FEDAC uptake.

This early study demonstrates that ¹⁸F-FEDAC makes it possible to see active inflammation sites in arthritic joints by targeting TSPO expression in activated macrophages, and it suggests imaging with ¹⁸F-FEDAC could be useful when RA is suspected.

Cheon points out, “Early treatment can reduce the progression of joint destruction and enhance the effect of disease-modifying antirheumatic drugs or target drugs, because the burden of inflammatory reaction is smaller in the very early phase of RA.” He notes, “We observed that ¹⁸F-FEDAC uptake increased in paws of murine RA models in association with TSPO expression of activated macrophages, even before the onset of clinical symptoms of arthritis. ¹⁸F-FEDAC can help us to find which patients will actually progress to clinically significant rheumatoid arthritis and need treatment.”

Source: Read Full Article